Fairmount: Funding, Team & Investors | Startup Intros

Loading organizations...

Fairmount: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Feb 18, 2026	Korsana Biosciences	$150.0M Series A	TCGX, Nilesh Kumar	Foresite Capital, Janus Henderson Investors, J.P. Morgan, Sanofi Ventures, Andrew Gottesdiener
Jan 12, 2026	Mirador Therapeutics	$250.0M Series B	—	Adage Capital Management, ARCH Venture Partners, Boxer Capital, Farallon Capital Management, Fidelity Management & Research Company, Invus, Logos Capital, OrbiMed, Point72, TCGX, T. Rowe Price Associates, Venrock, Woodline Partners
May 24, 2024	Bicycle Therapeutics	$555.0M Other Equity	—	Deep Track Capital, EcoR1 Capital, Forbion, Perceptive Advisors, RA Capital Management
May 1, 2024	Zenas BioPharma	$200.0M Series C	SR One Capital Management, Tim Xiao, NEA, Norwest Venture Partners	Vivo Capital, ArrowMark Partners, Enavate Sciences, Hermes GPE, Longitude Capital, Pivotal bioVenture Partners, Quan Capital, Rock Springs Capital, Superstring Capital, Wellington Management
Mar 1, 2024	Mirador Therapeutics	$400.0M Series A	ARCH Venture Partners	Cambridge Innovation Capital, HealthCap, Mubadala, Alexandria Venture Investments, Boxer Capital, Farallon Capital Management, Fidelity Management & Research Company, Invus, Logos Capital, OrbiMed, Point72, RTW Investments, Sanofi Ventures, TCGX, Venrock, Woodline Partners
Dec 1, 2023	Bicara Therapeutics	$170.0M Series C	Braidwell, Carolyn Ng	F-Prime Capital Partners, RA Capital, Red Tree Venture Capital, Samsara BioCapital, Third Rock Ventures, Aisling Capital, Deerfield Management
Nov 1, 2022	Zenas BioPharma	$120.0M Series B	James Boylan	venBio, Vivo Capital, Agent Capital, Patrick Enright, Perceptive Advisors, Pivotal bioVenture Partners, Quant Venture Fund, Rock Springs Capital, Superstring Capital, Tellus BioVentures, Wellington Management, Xencor
Oct 16, 2022	Enliven Therapeutics	$165.0M Other Equity	Fairmount, Venrock	Commodore Capital, Fidelity Management & Research Company, Frazier Life Sciences, RA Capital Management
May 1, 2021	Nuvalent	$140.0M Series B	Bain Capital Life Sciences	Abingworth, Deerfield Management, MRL Ventures Fund, RiverVest, SV Health Investors, Avoro Capital Advisors, Boxer Capital, Driehaus Capital Management, Fidelity Management & Research Company, Janus Henderson Investors, Logos Capital, Venrock, Viking Global Investors, Wellington Management
May 1, 2021	Interius BioTherapeutics	$76.0M Series A	Cormorant Asset Management, Tomas Kiselak	Agent Capital, Bain Capital Life Sciences, Cofounders Capital, American Cancer Society, BrightEdge, Knollwood Investment Advisory, Logos Capital, Longwood Fund, Osage University Partners, Quin Capital, RA Capital Management, Lonnie Moulder Jr, The Mark Foundation for Cancer Research, University of Pennsylvania
Jul 8, 2020	Cogent Biosciences	$104.4M Series A	Chris Cain	Acorn Bioventures, Ally Bridge Group, Bruce Booth, BVF Partners, Commodore Capital, Kiq, Logos Capital, OrbiMed, Perceptive Advisors, RTW Investments, Samsara BioCapital, Venrock